The PDX model market is projected to reach USD 839 million by 2028 from USD 426 million in 2023, at a CAGR of 14.5% during the forecast period. The key factors driving the growth of the global patient-derived xenograft/ PDX model market are the enhanced preclinical predictability, advancement of personalized medicine, and rise in the prevalence of cancer. However, ethical concerns surrounding the use of animal models along with high associated costs are expected to restrain market growth to a certain extent.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
The patient-derived xenograft/ PDX model market is categorized into five major categories: type, implantation method, tumor type, application, and end user. Based on type, the patient-derived xenograft/ PDX model market is segmented into mouse model and rat model. In 2023, the mouse model segment dominated the patient-derived xenograft/ PDX model market. Growth in this market segment can be attributed to biological similarities of the mice model with human tumors, and the availability of immunodeficient strains is expected to form the largest share segment in the patient-derived xenograft/ PDX model market.
Based on implantation method, the market is categorized into subcutaneous implantation, orthotopic implantation, and other implantation methods. In 2023, the subcutaneous segment accounted for the largest share of the patient-derived xenografts/ PDX models market. The major drivers are propelling the accessibility and ease of Implantation of the subcutaneous method and the cost and time efficiency of the method.
Based on tumor type, the patient-derived xenograft/ PDX model market is categorized into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. The hematological tumor models segment accounted for the fastest-growing segment of the tumor type segment of the patient-derived xenograft/ PDX model market. Market growth can largely be attributed to factors such a continuous rise in the incidence of hematological malignancies which is supporting research of treatments against hematological malignancies, and a growing focus on targeted therapies against cancer among others.
Based on application, the patient-derived xenograft/ PDX model market is segmented into preclinical drug development, biomarker analysis, translational research, and biobanking. Among these, the preclinical drug development application segment accounted for the largest share of the patient-derived xenografts/ PDX models application market. The major driver fueling the growth of the patient-derived xenografts/ PDX models market is a constant increase in the number of ongoing clinical trials and the use of PDX models in the development of personalized therapeutic regimens for oncology treatments.
Based on the end user, the segment is categorized into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2023, the pharmaceutical and biotechnology companies segment dominated the end-user segment with the highest revenue share. Collaborative projects amongst the pharmaceutical and biotechnology companies, rising numbers of drugs in the R&D pipeline, and increasing investment in R&D are propelling the growth of the pharmaceutical and biotechnology companies market.
Based on region, North America accounted for the largest share of the patient-derived xenografts/ PDX models market. The large share of the North American region can be attributed to extensive research focusing on novel oncology therapies, a rise in cancer prevalence, and increased adoption of personalized medicine. Moreover, the APAC region offers lucrative growth potential for the PDX models market. This can be attributed to the supportive regulatory framework, ongoing expansion and modernization of healthcare infrastructure across emerging Asian countries, and public-private initiatives to encourage awareness about personalized medicine.
Major players operating in the patient-derived xenograft/ PDX model market include JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US), EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).
Recent Developments in PDX Model Industry
In December 2022, Crown Bioscience, Inc., a subsidiary of JSR Life Sciences, entered into a worldwide licensing agreement with ERS Genomics Limited. This agreement granted Crown Bioscience complete global access to ERS’s foundational CRISPR/Cas9 patent portfolio, enabling the company to utilize CRISPR/Cas9 for genetic editing on a global scale. Under the provisions of this agreement, Crown Bioscience broadened its capabilities in genetic manipulation. The company is exploring the potential of gene editing within three-dimensional models of patient-derived tumor organoids.
In July 2022, GemPharmatech entered into a strategic licensing arrangement with Charles River Laboratories, Inc. This partnership entails the exclusive distribution rights for GemPharmatech’s advanced NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines within the North American region.
In November 2021, Inotiv announced the completion of the acquisition of Envigo RMS Holding Corp., a leading global provider of research models and services.
